The Patent and Trademark Office issued a favorable decision for Editas Medicine Inc. (Nasdaq: EDIT) in a patent dispute involving CRISPR/Cas9 genome editing. Shares of the genome editing company leaped $5.44 to closes at $24.30.
Editas Medicine receives favorable decision
February 15, 2017 at 19:06 PM EST
